Pseudomonas aeruginosa bloodstream infection: Importance of appropriate initial antimicrobial treatment

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 4, 2005, Pages 1306-1311

  Micek, Scott T ^a   Lloyd, Ann E ^a   Ritchie, David J ^a,b   Reichley, Richard M ^b   Fraser, Victoria J ^b   Kollef, Marin H ^b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BLOODSTREAM INFECTION; COHORT ANALYSIS; CONFIDENCE INTERVAL; DATA BASE; DEATH; DISEASE COURSE; DRUG USE; ELECTRONIC MEDICAL RECORD; FEMALE; GRAM NEGATIVE BACTERIUM; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; MONOTHERAPY; MORTALITY; NONHUMAN; PHARMACY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SEPTICEMIA; SHOCK; UNITED STATES;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; COHORT STUDIES; FEMALE; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES;

EID: 16244414846     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.4.1306-1311.2005     Document Type: Article

References (37)

1. Anonymous. 1998. All patient refined diagnosis related groups (APR-DRGs), version 15.0. 3M Health Information Systems. Wallingford, Conn.
2. Bailey, T. C., D. J. Ritchie, S. T. McMullin, M. Kahn, R. M. Reichley, E Casabar, W. Shannon, and W. C. Dunagan. 1997. A randomized prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teach institutions. Pharmacotherapy 17:277-281.
3. Bodey, G. P., L. Jadeja, and L. Elting. 1985. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch. Intern. Med. 145:1621-1629.
4. Bryan, C. S., K. L. Reynolds, and E. R. Brenner. 1983. Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev. Infect. Dis. 5:629-638.
5. Chamot, E., E. B. El Amari, P. Rohner, and C. van Delden. 2003. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 47:2756-2764.
6. Chatzinikolaou, I., D. Abi-Said, G. P. Bodey, K. V. Rolston, J. J. Tarrand, and G. Samonis. 2000. Recent experience with Pseudomonas aeruginosa in patients with cancer: retrospective analysis of 245 episodes. Arch. Intern. Med. 160:501-509.
7. Concato, J., A. R. Feinstein, and T. R. Holford. 1993. The risk of determining risk with multivariate models. Ann. Intern. Med. 118:201-210.
8. Dhainaut, J. F., P. F. Laterre, S. P. LaRosa, H. Levy, G. E. Garber, D. Heiselman, G. T. Kinasewitz, R. B. Light, P. Morris, R. Schein, J. P. Sollet, B. M. Bates, and B. G. Utterback. 2003. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS) role, methodology, and results. Crit. Care Med. 31:2291-2301.
9. El Amari, E. B., E. Chamot, R. Auckenthaler, J. C. Pechere, and C. van Delden. 2001. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin. Infect. Dis. 33:1859-1864.
10. Garnacho-Montero, J., J. L. Garcia-Garmendia, A. Barrero-Almodovar, F. J. Jimenez-Jimenez, C. Perez-Paredes, and C. Ortiz-Leyba. 2003. Impact of adequate empiric antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit. Care Med. 31:2742-2751.
11. Giamarellou, H. 1986. Aminoglycosides plus beta lactams against gram-negative organisms. Evaluation of in vitro synergy and clinical interactions. Am. J. Med. 80(Suppl. 6B):126-137.
12. Grisaru-Soen, G., L. Lerner-Geva, N. Keller, H. Berger, J. H. Passwell, and A. Barzilai. 2000. Pseudomonas aeruginosa bacteremia in children: analyses of trends in prevalence antibiotic resistance and prognostic factors. Pediatr. Infect. Dis. J. 19:59-63.
13. Harbarth, S., K. Ferriere, S. Hugonnet, B. Ricou, P. Sutter, and D. Pittet. 2002. Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care. Arch. Surg. 137:1353-1359.
14. Harbarth, S., J. Garbino, J. Pugin, J. A. Romand, D. Lew, and D. Pittet. 2003. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am. J. Med. 115:529-535.
15. Ibrahim, E. H., G. Sherman, S. Ward, V. J. Fraser, and M. H. Kollef. 2000. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118:146-155.
16. Ibrahim, E. H., S. Ward, G. Sherman, R. Schaiff, V. J. Fraser, and M. H. Kollef. 2001. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit. Care Med. 29:1109-1115.
17. Kollef, M. H. 2000. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin. Infect. Dis. 31:5131-S138.
18. Kollef, M. H., and V. J. Fraser. 2001. Antibiotic resistance in the intensive care unit. Ann. Intern. Med. 134:298-314.
19. Kollef, M. H., G. Sherman, S. Ward, and V. J. Fraser. 1999. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462-474.
20. Kollef, M. H., and S. Ward. 1998. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated associated pneumonia. Chest 113:412-420.
21. LeGall, J. R., P. Loirat, A. Alperovitch, P. Glaser, C. Granthil, D. Mathieu, P. Mercier, R. Thomas, and D. Villers. 1984. A simplified acute physiology score for ICU patients. Crit. Care Med. 12:975-977.
22. Lodise, T. P., P. S. McKinnon, L. Swiderski, and M. J. Rybak. 2003. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin. Infect. Dis. 36:1418-1423.
23. National Committee for Clinical Laboratory Standards. 1999. Performance standards for antimicrobial disk susceptibility tests. Document M2-A6, vol. 19, no. 1. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. Neuhauser, M. M., R. A. Weinstein, R. Rydman, L. H. Danziger, G. Haram, and J. P. Quinn. 2003. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289:885-888.
25. Osmon, S., S. Ward, V. J. Fraser, and M. H. Kollef. 2004. Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest 125:607-616.
26. Paul, M., I. Benuri-Silbiger, K. Soares-Weiser, and L. Leibovici. 2004. β-Lactam monotherapy versus β-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systemic review and meta-analysis of randomized trials. BMJ 328:668.
27. Paul, M., K. Soares-Weiser, and L. Leibovici. 2003. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. BMJ 326:1111.
28. Rello, J., M. Gallego, D. Mariscal, R. Sonora, and J. Valles. 1997. The value of routine microbial investigation in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 156:196-200.
29. Richards, M. J., J. R. Edwards, D. H. Culver, and R. P. Gayne. 1999. Nosocomial infections in medical intensive care units in the United States: National Nosocomial Infections Surveillance System. Crit. Care Med. 27:887-892.
30. Shen, Y. 2003. Applying the 3M all patient refined diagnosis related groups grouper to measure in-patient severity in the VA. Med. Care 41:11103-11110.
31. Trouillet, J. L., J. Chastre, A. Vuagnat, M. L. Joly-Guillou, D. Combaux, M. C. Dombret, and C. Gibert. 1998. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am. J. Respir. Crit. Care Med. 157:531-539.
32. Vidal, F., J. Mensa, M. Almela, J. A. Martinez, F. Marco, C. Casals, J. M. Gatell, E. Soriano, and M. T. Jimenez de Anta. 1996. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia. with special emphasis on the influence of antibiotic treatment: analysis of 189 episodes. Arch. Intern. Med. 156:2121-2126.
33. Vincent, J. L., D. J. Bihari, P. M. Suter, H. A. Braining, J. White, M. H. Nicholas-Chanoin, M. Wolff, R. C. Spencer, and M. Hemmer. 1995. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) study. JAMA 274:639-644.
34. Wade, J. C. 1989. Antibiotic therapy for the febrile granulocytopenic cancer patient: combination therapy vs. monotherapy. Rev. Infect. Dis. 11(Suppl. 7):S1572-S1581.
35. Weinstein, M. P., S. Mirrett, M. L. Wilson, L. G. Reimer, and L. B. Reller. 1994. Controlled evaluation of 5 versus 10 milliliters of blood cultured in aerobic BacT/Alert blood culture bottles. J. Clin. Microbiol. 32:2103-2106.
36. Weinstein, M. P., M. L. Towns, S. M. Quartey, S. Mirrett, L. G. Reimer, G. Parmigiani, and L. B. Reller. 1997. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin. Infect. Dis. 24:584-602.
37. Wisplinghoff, H., H. Seifert, S. M. Tallent, T. Bischoff, R. P. Wenzel, and M. B. Edmond. 2003. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features, and susceptibilities. Pediatr. Infect. Dis. J. 22:686-691.